Induction of mycobacterial resistance to quinolone class antimicrobials

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 7, 2012, Pages 3879-3887

  Malik, Muhammad ^a   Chavda, Kalyan ^a   Zhao, Xilin ^a,b   Shah, Nirali ^a   Hussain, Syed ^a   Kurepina, Natalia ^a   Kreiswirth, Barry N ^a   Kerns, Robert J ^c   Drlica, Karl ^a,b  

^a PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 CYCLOPROPYL 7 (3 ETHYL 1 PIPERAZINYL) 6 FLUORO 1,4 DIHYDRO 4 OXO 3 QUINOLINECARBOXYLIC ACID; BACTERIAL DNA; CIPROFLOXACIN; GATIFLOXACIN; ISONIAZID; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; UING 5 207; UING 5 249; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIUM CULTURE; BACTERIUM ISOLATE; BACTERIUM MUTANT; COLONY FORMING UNIT; CONTROLLED STUDY; DNA REPLICATION; DNA SEQUENCE; DRUG STRUCTURE; ENRICHMENT CULTURE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIOSIS; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TUBERCULOSIS;

ANTI-INFECTIVE AGENTS; ANTITUBERCULAR AGENTS; AZA COMPOUNDS; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; MYCOBACTERIUM TUBERCULOSIS; OFLOXACIN; QUINOLINES;

EID: 84862587394     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00474-12     Document Type: Article

References (65)

1. Barnes P, Cave M. 2003. Molecular epidemiology of tuberculosis. N. Engl. J. Med. 349:1149-1156. (Pubitemid 37122328)
2. Bax B, et al. 2010. Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature 466:935-940.
3. Bonilla C, et al. 2008. Management of extensively drug-resistant tuberculosis in Peru: cure is possible. PLoS One 3:e2957.
4. Boshoff H, Reed M, Barry C, Mizrahi V. 2003. DnaE2 polymerase contributes to in vivo survival and the emergence of drug resistance in Mycobacterium tuberculosis. Cell 113:183-193. (Pubitemid 36514970)
5. Brudey K, et al. 2006. Mycobacterium tuberculosis complex genetic diversity: mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics and epidemiology. BMC Microbiol. 6:23.
6. Caminero J, Sotgiu G, Zumla A, Migliori G. 2010. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect. Dis. 10:621-629.
7. Cirz R, et al. 2005. Inhibition of mutation and combating the evolution of antibiotic resistance. PLoS Biol. 3:e176.
8. Cirz R, Romesberg F. 2006. Induction and inhibition of ciprofloxacin resistance-conferring mutations in hypermutator bacteria. Antimicrob. Agents Chemother. 50:220-225. (Pubitemid 43042924)
9. Dong Y, Xu C, Zhao X, Domagala J, Drlica K. 1998. Fluoroquinolone action against mycobacteria: effects of C8 substituents on bacterial growth, survival, and resistance. Antimicrob. Agents Chemother. 42:2978-2984. (Pubitemid 28501236)
10. Drlica K, Zhao X. 2007. Mutant selection window hypothesis updated. Clin. Infect. Dis. 44:681-688.
11. Ebrahimi-Rad M, et al. 2003. Mutations in putative mutator genes of Mycobacterium tuberculosis strains of the W-Beijing family. Emerg. Infect. Dis. 9:838-845.
12. Gandhi NR, et al. 2006. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368:1575-1580. (Pubitemid 44780738)
13. German N, Malik M, Rosen J, Drlica K, Kerns R. 2008. Use of gyrase resistance mutants to guide selection of 8-methoxy-quinazoline-2,4-diones. Antimicrob. Agents Chemother. 52:3915-3921.
14. Ginsberg A. 2010. Drugs in development for tuberculosis. Drugs 70:2201-2214.
15. Gocke E. 1991. Mechanism of quinolone mutagenicity in bacteria. Mutat. Res. 248:135-143.
16. Gudas LJ, Pardee AB. 1976. DNA synthesis inhibition and the induction of protein X in Escherichia coli. J. Mol. Biol. 101:459-477.
17. Inouye M, Pardee A. 1970. Changes of membrane proteins and their relation to deoxyribonucleic acid synthesis and cell division of Escherichia coli. J. Biol. Chem. 245:5813-5819.
18. Jacobs WR, et al. 1991. Genetic systems in mycobacteria. Methods Enzymol. 204:537-555.
19. Jacobson K, Tierney D, Jeon C, Mitnick C, Murray M. 2010. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin. Infect. Dis. 51:6-14.
20. Karunakaran P, Davies J. 2000. Genetic antagonism and hypermutability in Mycobacterium smegmatis. J. Bacteriol. 182:3331-3335. (Pubitemid 30341592)
21. Kim S, et al. 1997. Multiple pathways for SOS-induced mutagenesis in Escherichia coli: an overexpression of dinB/dinP results in strongly enhancing mutagenesis in the absence of any exogenous treatment to damage DNA. Proc. Natl. Acad. Sci. U. S. A. 94:13792-13797. (Pubitemid 28009663)
22. Kohanski M, Dwyer D, Hayete B, Lawrence C, Collins J. 2007. A common mechanism of cellular death induced by bactericidal antibiotics. Cell 130:797-810. (Pubitemid 47332566)
23. Kong Y, et al. 2007. Association between Mycobacterium tuberculosis Beijing/W lineage strain infection and extrathoracic tuberculosis: insights from epidemiologic and clinical characterization of the three principal genetic groups of M. tuberculosis clinical isolates. J. Clin. Microbiol. 45:409-414.
24. Laponogov I, et al. 2010. Structural basis of gate-DNA breakage and resealing by type II topoisomerases. PLoS One 5:e11338.
25. Laponogov I, et al. 2009. Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases. Nat. Struct. Mol. Biol. 16:667-669.
26. Lari N, Rindi L, Bonanni D, Tortolli E, Garzelli C. 2006. Mutations in mutT genes of Mycobacterium tuberculosis isolates of Beijing genotype. J. Med. Microbiol. 55:599-603.
27. Lewin C, Howard B, Ratcliffe N, Smith J. 1989. 4-Quinolones and the SOS response. J. Med. Microbiol. 29:139-144. (Pubitemid 19171551)
28. Little J. 1993. LexA cleavage and other self-processing reactions. J. Bacteriol. 175:4943-4950. (Pubitemid 23232553)
29. Maciá M, et al. 2005. Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. Antimicrob. Agents Chemother. 49:3382-3386.
30. Maguin E, Lutkenhaus J, D'Ari R. 1986. Reversibility of SOS-associated division inhibition in Escherichia coli. J. Bacteriol. 166:733-738. (Pubitemid 16098149)
31. Malik M, Hoatam G, Chavda K, Kerns R, Drlica K. 2010. Novel approach for comparing abilities of quinolones to restrict the emergence of resistant mutants during quinolone exposure. Antimicrob. Agents Chemother. 54:149-156.
32. Malik M, et al. 2005. Lethality of quinolones against Mycobacterium smegmatis in the presence or absence of chloramphenicol. Antimicrob. Agents Chemother. 49:2008-2014. (Pubitemid 40631619)
33. Malik M, et al. 2011. Fluoroquinolone and quinazolinedione activity with wild-type and gyrase mutants of Mycobacterium smegmatis. Antimicrob. Agents Chemother. 55:2335-2343.
34. Mamber S, Kolek B, Brookshire K, Bonner D, Fung-Tomc J. 1993. Activity of quinolones in the Ames Salmonella TA102 mutagenicity test and other bacterial genotoxicity assays. Antimicrob. Agents Chemother. 37:213-217. (Pubitemid 23046557)
35. Miller C, et al. 2004. SOS response induction by β-lactams and bacterial defense against antibiotic lethality. Science 305:1629-1631. (Pubitemid 39296359)
36. Miller JH, Low KB. 1984. Specificity of mutagenesis resulting from the induction of the SOS system in the absence of mutagenic treatment. Cell 37:675-682. (Pubitemid 14079061)
37. Mitnick C, Castro K, Harrington M, Sacks L, Burman W. 2007. Randomized trials to optimize treatment of multidrug-resistant tuberculosis. PLoS Med. 4:e292.
38. Mitnick C, et al. 2008. Comprehensive treatment of extensively drug-resistant tuberculosis. N. Engl. J. Med. 359:563-574.
39. Morero N, Monti M, Argaraña CE. 2011. Effect of ciprofloxacin concentration on the frequency and nature of resistant mutants selected from Pseudomonas aeruginosa mutS and mutT hypermutators. Antimicrob. Agents Chemother. 55:3668-3676.
40. Musser J. 2001. Single nucleotide polymorphisms in Mycobacterium tuberculosis structural genes. Emerg. Infect. Dis. 7:486-488.
41. Musser J, Amin A, Ramaswamy S. 2000. Negligible genetic diversity of Mycobacterium tuberculosis host immune system protein targets: evidence of limited selective pressure. Genetics 155:7-16. (Pubitemid 30257106)
42. Napolitano R, Janel-Bintz R, Wagner J, Fuchs R. 2000. All three SOS-inducible DNA polymerases (Pol II, Pol IV and Pol V) are involved in induced mutagenesis. EMBO J. 19:6259-6265.
43. Oishi M, Smith CL, Friefeld B. 1979. Molecular events and molecules that lead to induction of prophage and SOS functions. Cold Spring Harbor Symp. Quant. Biol. 43:897-907. (Pubitemid 9234608)
44. Oliver A, Canton R, Campo P, Baquero F, Blazquez J. 2000. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 288:1251-1253. (Pubitemid 30367204)
45. Oliver A, Levin B, Juan C, Baquero F, Blazquez J. 2004. Hypermutation and the preexistence of antibiotic-resistant Pseudomonas aeruginosa mutants: implications for susceptibility testing and treatment of chronic infections. Antimicrob. Agents Chemother. 48:4226-4233. (Pubitemid 39434879)
46. Phillips I. 1987. Bacterial mutagenicity and the 4-quinolones. J. Antimicrob. Chemother. 20:771-773. (Pubitemid 18033958)
47. Piddock LJV, Wise R. 1987. Induction of the SOS response in Escherichia coli by 4-quinolone antimicrobial agents. FEMS Microbiol. Lett. 41(3):289-294. (Pubitemid 17103437)
48. Piddock LJ, Walters RN, Diver JM. 1990. Correlation of quinolone MIC and inhibition of DNA, RNA, and protein synthesis and induction of the SOS response in Escherichia coli. Antimicrob. Agents Chemother. 34:2331-2336.
49. Power E, Phillips I. 1993. Correlation between umuC induction and Salmonella mutagenicity assay for quinolone antimicrobial agents. FEMS Microbiol. Lett. 112:251-254. (Pubitemid 23280691)
50. Quan S, Venter H, Dabbs E. 1997. Ribosylative inactivation of rifampin by Mycobacterium smegmatis is a principle contributor to its low susceptibility to this antibiotic. Antimicrob. Agents Chemother. 41:2456-2460. (Pubitemid 27467556)
51. Rodrigues L, Ramos J, Couto I, Amaral L, Viveiros M. 2011. Ethidium bromide transport across Mycobacterium smegmatis cell-wall: correlation with antibiotic resistance. BMC Microbiol. 11:35.
52. Sanders L, Rockel A, Lu H, Wozniak D, Sutton M. 2006. Role of Pseudomonas aeruginosa dinB-encoded DNA polymerase IV in mutagenesis. J. Bacteriol. 188:8573-8585. (Pubitemid 44894058)
53. Saunders NJ, et al. 2011. Deep resequencing of serial sputum isolates of Mycobacterium tuberculosis during therapeutic failure due to poor compliance reveals stepwise mutation of key resistance genes on an otherwise stable genetic background. J. Infect. 62:212-217.
54. Sieradzki K, Roberts R, Haber S, Tomasz A. 1999. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N. Engl. J. Med. 340:517-523. (Pubitemid 29093287)
55. Smith B, Walker G. 1998. Mutagenesis and more: umuDC and the Escherichia coli SOS response. Genetics 148:1599-1610. (Pubitemid 28180689)
56. Snyder M, Drlica K. 1979. DNA gyrase on the bacterial chromosome: DNA cleavage induced by oxolinic acid. J. Mol. Biol. 131:287-302. (Pubitemid 9230184)
57. Sreevatsan S, et al. 1997. Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionary recent global dissemination. Proc. Natl. Acad. Sci. U. S. A. 94:9869-9874. (Pubitemid 27408157)
58. Wang J, et al. 2010. Adding moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 14:65-71.
59. Wang X, Zhao X. 2009. Contribution of oxidative damage to antimicrobial lethality. Antimicrob. Agents Chemother. 53:1395-1402.
60. Wang X, Zhao X, Malik M, Drlica K. 2010. Contribution of reactive oxygen species to pathways of quinolone-mediated bacterial cell death. J. Antimicrob. Chemother. 65:520-524.
61. Wohlkonig A, et al. 2010. Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance. Nat. Struct. Mol. Biol. 17:1152-1153.
62. World Health Organization. 2010. Multidrug and extensively drug-resistant TB (M/XDR-TB) 2010 global report on surveillance and response. World Health Organization, Geneva, Switzerland. http://whqlibdoc.who.int/publications/2010/ 9789241599191-eng.pdf.
63. Yang H, Wolff E, Kim M, Diep A, Miller J. 2004. Identification of mutator genes and mutational pathways in Escherichia coli using a multi-copy cloning approach. Mol. Microbiol. 53:283-295. (Pubitemid 38901398)
64. Zhao X, Drlica K. 2001. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin. Infect. Dis. 33(Suppl 3):S147-S156. (Pubitemid 32835784)
65. Zhou J, et al. 2000. Selection of antibiotic resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutations. J. Infect. Dis. 182:517-525. (Pubitemid 30651049)